Compare Travere Therapeutics Inc. Common Stock (TVTX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while State Street Technology Select Sector SPDR ETF trades at $187.9 (market cap $129.38B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 26.5× Travere Therapeutics Inc. Common Stock's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| TVTX | XLK | |
|---|---|---|
Market Cap | $4.88B | $129.38B |
Volume | 1,668,577 | 6,753,008 |
Sector | Health | Sector/Thematic |
52-Week High | $67.52 | $202.00 |
52-Week Low | $26.79 | $127.49 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLK trades at $196.24, down slightly by 0.06% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF faces concentration concerns despite its tech sector exposure, with recent news highlighting AI-driven opportunities and potential interest rate impacts. Support levels are established at $195 and $194, with resistance at $198 and $199.
The outlook for XLK remains positive given strong AI investment themes and large-cap tech resilience, though risks include Fed rate hike sensitivity and sector concentration. Investor sentiment is mixed, balancing growth potential against macroeconomic headwinds and valuation pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
